Back to results
US 2023/0055407 A1Published application
V-c-fc-v-c antibody
AssigneeAmgen Inc.
InventorsMark L. Michaels, Luis G. Borges, Wei Yan
Life of this patent
Estimating the term…
Abstract
Described herein is a dimeric, bispecific antibody format. Each polypeptide chain of the dimer comprises an immunoglobulin variable region, an immunoglobulin constant region, an Fc polypeptide chain, another immunoglobulin variable region, and another immunoglobulin constant region. Also described are methods of making and using such antibodies.
Claims30
An antibody comprising two polypeptide chains,
- the first polypeptide chain comprising the following regions, which may or may not be separated by linkers, in the following order in an N- to C-terminal direction:
- V-1-C-1-hinge-CH2-1-CH3-1-V-2-C-2;
- and
- the second polypeptide chain comprising the following regions, which may or may not be separated by linkers, in the following order in an N- to C-terminal direction:
- V-3-C-3-hinge-CH2-2-CH3-2-V-4-C-4;
- wherein the V-1 to V-4 regions are immunoglobulin variable regions;
- wherein the C-1 to C-4 regions are either a heavy chain constant region 1 (CH1) or a light chain constant region (CL), and if C-1 is a CH1, then C-3 is a CL and vice versa, and if C-2 is a CH1, then C-4 is a CL and vice versa;
- and
- wherein the CH2-1 and CH2-2 are each a heavy chain constant region 2 and the CH3-1 and CH3-2 are each a heavy chain constant region 3.
6 more elements
3-9. (canceled)
13-16. (canceled)
(canceled)
22-23. (canceled)
26-27. (canceled)
(canceled)
(canceled)
An antibody comprising a first polypeptide chain having the following formula:
- V-1-L-3-C-1-L-4-hinge-CH2-1-CH3-1-L-1-V-2-L-5-C-2 and a second polypeptide chain having the following formula:
- V-3-L6-C-3-L7-hinge-CH2-2-CH3-2-L-2-V-4-L-8-C-4,
- wherein the V-1, V-2, V-3, and V-4 are immunoglobulin variable regions having different amino acid sequences,
- wherein either the V-1 or the V-3 is a VH, and if the V-1 is a VH, then the V-3 is a VL, and if the V-3 is a VH, then the V-1 is a VL,
- wherein either the V-2 or the V-4 is a VH, and if the V-2 is a VH, then the V-4 is a VL, and if the V-4 is a VH, then the V-2 is a VL,
- wherein the L-1, L-2, L-3, L-4, L-5, L-6, L-7, and L-8 are linkers and L-3, L-4, L-5, L-6, L-6, and L-8 can be present or absent,
- wherein either the C-1 or the C-3 is a CH1, and if the C-1 is a CH1, then the C-3 is a CL, and if the C-3 is a CH1, then the C-1 is a CL,
- wherein either the C-2 or the C-4 is a CH1, and if the C-2 is a CH1, then the C-4 is a CL, and if the C-4 is a CH1, then the C-2 is a CL, and
- wherein the antibody binds to a cancer cell and to an immune effector cell.
6 more elements
37-38. (canceled)
(canceled)
42-56. (canceled)
Dependencies are inferred from the claim text.